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Development of the bovine mammary gland is a complex process that is regulated 
by several hormones, growth factors and transcription factors including but not limited to 
growth hormone (GH), insulin-like growth factor (IGF)-I and T-box (Tbx)2 and 3. Tbx2 
and Tbx3 are transcription factors required for mammary gland development in humans 
and known to regulate cell cycle. In addition, there is recent evidence that GH increases 
expression of Tbx3 in osteoblasts independent of IGF-I. Based on these findings, we 
hypothesized GH and IGF-I will increase Tbx2 and Tbx3 expression in bovine mammary 
epithelial cells (MEC), the cell responsible for milk production. To test our hypothesis, 
MAC-T cells (MEC line) were treated with GH at 100 (GH100) or 500 (GH500) ng/mL 
or IGF-I at 100 (IGF100) or 200 (IGF200) ng/mL for 24 and 48 hours.  As determined by 
real-time RT-PCR, we did not observe a change in Tbx3 expression in cells treated with 
GH (P ≥ 0.74). However, both IGF-I treatments increased Tbx3 expression (P ≤ 0.03). 
Surprisingly, expression of Tbx2 was not detectable in MEC cells; however it was 
expressed in mammary fibroblast cells.  In fibroblast cells treated with GH500 and 
IGF200, we did observe a change in Tbx2 or Tbx3 expression (P ≥ 0.76).  In conclusion, 
IGF-I regulates Tbx3 expression in bovine MEC and Tbx2 and Tbx3 expression are cell 
type specific.  
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REVIEW OF LITERATURE 
 
 
Introduction 
Within the United States dairy industry, maintaining udder health and maximizing 
efficiency of production is essential for a dairy operation to be profitable. In 2009, the 
United States dairy industry generated $24.3 billion dollars in revenue from dairy sales 
(USDA: NASS, 2009). However, with rising costs of feed, it is becoming increasingly 
more expensive to produce milk. For example, between 2005 and 2007 there was a 110% 
increase in corn prices and a 59% increase in alfalfa prices (USDA: NASS, 2010). When 
feed prices increase significantly, it not only increases the cost of producing milk, but 
also reduces the profit made by the producer. As a result, farmers need to alter their 
management practices to maximize efficiency in an effort to maintain a profitable dairy 
operation. Efficiency of production can be impacted in several ways, one of which is 
animal health.  
 In 2006, 23% of all dairy cattle culled from herds suffered from either mastitis or 
other mammary gland abnormalities. An additional 16.1% of animals culled were due to 
poor production (USDA: APHIS, 2007). This demonstrates that poor udder health and 
function is accounting for 40% of the animal losses within the dairy industry and 
therefore is an issue within dairy production. In an effort to improve efficiency of 
production and udder health, research has focused on key elements within the mammary 
gland in order to better understand mammary gland function. The data obtained from 
these studies can be used to improve udder health and milk production which in turn will 
benefit the dairy industry. Specifically, our research focuses on understanding the 
mechanisms involved in regulating mammary gland development and its response to key 
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hormones and growth factors. This literature review will focus on general mammary 
gland anatomy, development and function, as well as, discuss how the function of the 
mammary gland is regulated in response to specific hormones, growth factors, and 
transcription factors.  
 
Bovine Mammary Gland Anatomy 
Understanding the structure of the gland is necessary not only in production 
agriculture but in mammary research. The bovine mammary gland can be divided into 
three segments: 1) The mammary fat pad, 2) The stroma, and 3) The parenchyma 
(Tucker, 1987). Each segment of the mammary gland contributes to the overall function 
of the gland which is to produce milk and its components (protein, fat and 
carbohydrates).  
 The mammary fat pad is a large deposition of fat on the dorsal aspect of the 
bovine mammary gland and infiltrates into the mammary stroma. The mammary fat pad 
plays a role in the ductile branching that occurs in mammary development, especially 
during embryonic stages (Watson and Khaled, 2008). The stroma of the mammary gland 
contains the support elements and connective tissue that surrounds the parenchyma. The 
stroma is comprised of several cell types (fibroblasts, adipocytes, and myoepithelial 
cells), collagen, lymphatic vessels and a vascular system (Akers, 2002; Connor et al., 
2007). In addition to providing support for the parenchyma, stromal tissue facilitates the 
paracrine actions of growth factors that are required for proper mammary development 
(Akers, 2006; Flint and Knight, 1997). The functions and roles of these growth factors 
will be discussed in more detail later in the review. While the mammary fat pad and 
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stroma play both supportive and developmental roles within the mammary gland they are 
not responsible for the production of milk. 
 The parenchyma is the portion of the mammary gland that is considered to be the 
functional aspect of the gland as this region contains the mammary epithelial cells 
(MEC). Mammary epithelial cells are responsible for producing milk which includes milk 
proteins, carbohydrates and fats (Akers, 2002). As a result, MEC are the focus of the 
majority of mammary gland research in cattle (De Vries et al., 2010). In the mammary 
gland, there are two main types of epithelial cells; luminal and basal epithelial cells 
(Watson and Khaled, 2008). The basal epithelium is comprised of the myoepithelial cells 
which aid in milk ejection from the gland. The luminal epithelial cells are comprised of 
two cell types: 1) ductile epithelial cells and 2) secretory epithelial cells (Watson and 
Khaled, 2008). The secratory epithelial cells line the walls of the alveolus and are 
responsible for milk production (Watson and Khaled, 2008). Each individual alveolus is 
grouped into lobules which are comprised of many alveoli. These cells are the focus of 
our research and the literature review will focus on growth and development of these 
cells from this point forward. 
     
                                    Mammary Gland Growth and Development    
Mammary development occurs during four stages in mammals: 1) embryonic, 2) pubertal 
(pre and post), 3) pregnancy, and 4) lactation (Akers, 2002; Tucker, 1987; Platonova et 
al., 2007).  Within these stages, physiologic and anatomical changes will occur that are 
specific to that phase of mammary development. 
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Embryonic Mammary Development 
Mammary development in the bovine commences with the formation of the 
mammary band which occurs at day 30 of embryonic development (Akers, 2002). The 
formation of the mammary band originates from the ectoderm germ layer of the embryo. 
This occurs with the aid of several transcription factors and cell signals that are present at 
different points throughout embryonic mammary development (See Tbx2 and Tbx3 in 
Mammary Gland Development). In the absence of these factors, mammary gland 
formation will arrest or fail to occur. From the structure of the mammary band, the 
mammary bud will form by day 40 of embryonic development in cattle (Akers, 2002).  
Embryonic mammary development will continue and eventually cease once the 
rudimentary gland has been established (Hens and Wysolmerski, 2005; Watson and 
Khaled, 2008). 
 
Pubertal Mammary Development 
Mammary development that occurs during puberty is synonymous with ductile 
development and branching as opposed to lobulo-alveolar development which does not 
occur until pregnancy (Tucker, 1987). In regards to mammary tissue growth, the stromal 
elements of the mammary gland grow prior to puberty. In addition to stromal tissue 
growth, allometric growth of the duct system of the mammary gland occurs just prior to 
the onset of puberty (Tucker, 1987). Mammary development during this stage is 
facilitated through the production of ovarian steroid (i.e., estrogen) resulting from the 
onset of ovarian development (See Hormones and Growth Factors section). Allometric 
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growth of the gland will continue through the initial estrus cycles after which the 
mammary gland will continue isometric growth until the animal becomes pregnant 
(Tucker, 1987).  
 
Gestational and Lactational Mammary Development 
 Mammary development during pregnancy is synonymous with the establishment 
of the lobulo-alveolar system. In addition to the development of these mammary 
structures, several other changes occur in the anatomy of the mammary gland at this 
stage. Prior to pregnancy the stroma is the more predominate tissues in the mammary 
gland. During pregnancy, mammary ducts will elongate and there will be an increase in 
mammary cell proliferation and alveoli formation. As result, these alveoli will replace the 
mammary fat pad and “rearrange” the stromal elements of the mammary gland resulting 
in the parenchyma becoming the dominate tissue type (Tucker, 1987). This change in 
tissue predominance is necessary for the mammary gland to prepare for lactation. As 
observed during puberty, allometric growth of the mammary gland will occur. This trend 
in growth will continue, resulting in a 25% increase in the mass of the parenchyma with 
every month of gestation (Swanson and Poffenbarger, 1979; Tucker, 1987).   
Within the mammary gland, proliferation of MEC is needed in order to maximize 
milk production. Cellular proliferation can be increased during pregnancy and lactation 
through the action of hormones and growth factors (i.e., IGF-I; see Hormones and 
Growth Factors section). Mammary epithelial cell proliferation will eventually slow 
which correlates with the stage of lactation when milk yield begins to decrease (Tucker, 
1987). 
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Mammary Epithelial Cell Development 
On the cellular level, MEC must also change cytologically in order to be capable 
of milk production. Organelles within the cell, specifically the Golgi apparatus and the 
endoplasmic reticulum, are responsible for the production of milk components. Therefore 
these organelles must undergo significant changes during pregnancy and lactation.  In 
non-pregnant cattle, the Golgi apparatus and endoplasmic reticulum (ER) are 
underdeveloped. This is in contrast to late gestation and lactation in which the ER will 
produce milk proteins and fatty acids while the Golgi apparatus will synthesize lactose, 
process casein proteins and package cellular products (Akers, 2002; Oka and Yoshimura, 
1986; Mills and Topper, 1970). In order for these cytological changes to occur there must 
be differentiation of MEC. Differentiation of the MEC requires the presence of several 
hormones, two of which are glucocorticoids and prolactin. Glucocorticoids are needed to 
develop the rough ER and prolactin is needed for the maturation of the Golgi apparatus as 
well as the secretory vesicles (Akers, 2002; Mills and Topper, 1970). Once MEC have 
proliferated and differentiated, with the aid of hormones and growth factors, the 
mammary gland is then capable of lactation. 
 
Regulation of Mammary Development 
The development of the mammary gland is a complex process that consists of 
many stages. Therefore, it is not surprising that there is a considerable amount of 
regulation that occurs throughout mammary gland development. Key regulatory factors 
of mammary development include 1) hormones, 2) growth factors, and 3) transcription 
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factors. Understanding the roles of these regulatory mechanisms in MEC function allows 
for a better understanding of the mammary gland. These regulatory factors will be the 
focus of the remainder of this literature review. 
 
Hormones and Growth Factors 
Estrogen     
The ovarian steroid, estrogen, aids in the growth of the mammary gland by 
facilitating ductile system development and assisting in the establishment of the lobulo-
alveolar system during pregnancy (Connor et al., 2007).  Like all hormones and growth 
factors, receptors must be present on a specific tissue type in order for the action of the 
hormone to be carried out.  Within mammary tissue, estrogen receptors are present on the 
ductile MEC, which coincides with the role of estrogen in ductile development (Capuco 
et al., 2002). One of the ways that estrogen facilities ductile development within the 
mammary gland is by increasing proliferation of MEC. This was observed in studies 
where animals were treated with exogenous estrogen and an increase in ductile MEC was 
observed (Woodward et al., 1993; Connor et al., 2007).  
In addition, growth of the mammary gland in the absence of estrogen has been 
evaluated through the use of overiectomized animals. In 2007, Connor et al, evaluated 
mammary development in overiectomized heifers compared to a group of control 
prepubertal heifers (Connor et al., 2007). It was observed that in overioectomized heifers 
there is a decreased amount of epithelial cell proliferation in the mammary gland. 
However within this study, mammary development was restored in ovariectomized 
animals when exogenous estrogen was administered (Connor et al., 2007), thus 
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demonstrating that estrogen is needed during prepubertal and pubertal mammary gland 
development.  
 
Prolactin 
The hormone prolactin also plays a critical role during mammary development. 
Secreted by the anterior lobe of the pituitary gland, prolactin is responsible for inducing 
MEC differentiation (Riley et al., 2009). Prolactin regulates several transcription factors 
(i.e., STAT-5 and ELF-5) during differentiation and facilitates the production of casein, a 
major milk protein, in differentiated cells. Prolactin facilitates these changes by 
interacting with specific cell signaling pathways (i.e., Jak2-Stat5: Riley et al., 2009) 
which will be discussed in the transcription factor portion of this literature review. 
 
Growth Hormone 
Growth hormone has been demonstrated to have a positive effect on lactation in 
cattle and is commonly used in commercial dairy operations to improve production. 
Growth hormone, also known as bovine somatotropin (bST), increases milk yield in the 
bovine by partitioning nutrients to the mammary gland for use in milk production 
(Bauman, 1999). In regards to mammary development, studies in rodents have 
determined that GH is needed for proper growth of mammary ducts during puberty and 
the development of the lobulo-alveolar system during pregnancy (Kleinberg and Ruan, 
2008).  
Growth hormone can act on target tissues through two mechanisms: 1) indirect 
action and 2) direct action. Within both mechanisms, GH is released from the anterior 
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lobe of the pituitary gland in response to growth hormone releasing factor (GRF). 
Alternately, GH release is inhibited through the actions of somatostatin (Roelfsema and 
Clark, 2001; Renaville et al., 2002). When GH acts indirectly, GH will bind receptors 
present on tissue (bone, adipose, and muscle, liver) and cause the production and release 
of the somatomedian, IGF-I. Insulin-like growth factor-I will in turn carry out the actions 
of GH on specific tissues. It is through GH binding to the liver and causing production of 
IGF-I that GH acts indirectly on mammary tissue (Kleinberg and Ruan, 2008; Cohick, 
1998). Growth hormone can also act directly on target tissues such as the bone, muscle, 
and adipose (Le Roith et al., 2001; Govoni et al., 2006). In order for there to be direct 
action of GH on a tissue, functional GH receptors (GHR) must be present (Le Roith et al., 
2001). Unlike the aforementioned tissues, it is questionable as to whether a functional 
GHR is present within the mammary gland (Akers, 2002; Cohick, 1998).  
Studies have demonstrated that GHR mRNA and receptor protein are present in 
the bovine mammary gland (Plath and Gabler, 2001). In contrast, early experiments 
which conducted ligand binding assays were not able to detect binding of GH to the GHR 
of mammary tissue (Akers, 2002). It is hypothesized that GH is able to act directly on the 
stromal elements of the mammary gland (Flint and Knight, 1997). Specifically, the 
fibroblasts within the stroma are responsive to GH treatment (Flint and Knight, 1997). In 
response to GH, fibroblast cells will produce IGF-I. This locally produced IGF-I will act 
on the surrounding tissue in a paracrine action and it is believed that this IGF-I plays a 
critical role in the mammary gland development (Baumrucker and Erondu, 2000; Flint 
and Knight, 1997). This also suggests that the stroma of the mammary gland plays a role 
beyond a structural support element.    
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Insulin-Like Growth Factor-I 
Insulin-like growth factor-I has been found to regulate cell cycle, increase 
proliferation, and prevent apoptosis of MEC (Cohick, 1998). The mechanisms through 
which IGF-I regulates cell cycle was evaluated in mice where treatment with IGF-I 
increased several cyclin molecules, in particular cyclin D1 and cyclin E (Stull et al., 
2004). These molecules are needed within the G1 phase of the cell cycle. Within this 
phase, the cell increases in size and prepares for the S phase, where DNA replication will 
occur (Stull et al., 2004). A relationship has been found between the concentrations of 
IGF-I in the blood of the animal and stage of mammary development. Specifically, IGF-I 
concentrations increase during pregnancy and then decreases immediately following 
parturition (Baumrucker and Erondu, 2000). However, as the lactation period advances 
IGF-I concentrations in the blood will continue to increase (Baumrucker and Erondu, 
2000). The increase in IGF-I concentrations during lactation could be a way through 
which apoptosis of existing MEC is prevented, thus sustaining lactation for a prolonged 
period of time.  
The need for IGF-I for mammary development has been demonstrated in several 
experiments. Studies using IGF-I knockout mice have demonstrated that animals 
deficient in IGF-I lack proper mammary development which is not restored when treated 
with GH (Kleinberg and Ruan, 2008). These results suggest that IGF-I may be mediating 
the actions of GH on the mammary gland during development as well (Kleinberg and 
Ruan, 2008).  
In summary, hormones and growth factors are key regulators of the different 
stages of mammary development. In particular, they facilitate growth of the different 
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structural elements of the gland (ductile and lobuloaleveolar system) as well as the 
development and differentiation of MEC. However there is also another subset of 
regulatory elements that are needed throughout mammary gland development and are 
directly involved in gene expression. These elements are transcription factors. 
 
Transcription Factors 
One of the ways in which hormones and growth factors can facilitate mammary 
growth and development is through transcription factors. Three transcription factors are 
needed during mammary development are GATA binding protein-3 (GATA-3), signal 
transducer and activator of transcription-5 (STAT-5), and ets transcription factor-5 (ELF-
5) (Oakes et al., 2006; Siegal and Muller, 2010). 
 
GATA-3 
GATA-3 is a transcription factor that has been found to be involved in luminal 
mammary cell type specification and maintains differentiated mammary epithelial cells 
(Siegel and Muller, 2010). In mice, the use of a cre/lox system to conditionally disrupt 
GATA-3 resulted in a knockdown of GATA-3 function in the mammary gland. In these 
mice, the MEC lacked the ability to differentiate. As a result, these animals demonstrated 
improper lobulo-alveolar development and did not lactate or produce milk proteins like 
the wild type animals (Siegal and Muller, 2010). This demonstrates that GATA-3 is 
necessary for differentiation of MEC and proper mammary development for lactation to 
occur. 
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Signal Transducer and Activator of Transcription-5 (STAT-5) 
 Another transcription factor that regulates mammary development is STAT-5. 
Signal transducer and activator of transcription-5 expression is induced by prolactin and 
is responsible for aiding in alveolar development, establishing cellular polarity, milk 
protein production and cell-cell interactions (Oakes et al., 2006). By conditionally 
knocking-down STAT5A and STAT5B gene expression, researchers observed a decrease 
in MEC differentiation in pregnant animals and a failure of these animals to lactate 
(Siegel and Muller, 2010). In STAT5 knockout animals there was also a decrease in the 
number of luminal alveolar progenitor cells (Siegal and Muller, 2010). However, if 
expression of this gene was restored, the mice resumed the normal mammary phenotype  
(Siegal and Muller, 2010). This demonstrates the role of STAT-5 in establishing 
differentiated mammary epithelial cells. 
 
Ets Transcription Factor-5 (ELF-5) 
Ets transcription factor-5, like GATA-3 and STAT5, is responsible for controlling 
alveolar development. This transcription factor, like GATA-3, plays a role in switching 
the mammary gland from a state of cellular proliferation to cellular differentiation during 
pregnancy. Ets transcription factor-5 expression is induced by prolactin. This was 
determined through the use of prolactin-receptor deficient mice (Oakes et al., 2006). 
Similar to the other transcription factors, a knockdown of ELF-5 gene expression results 
in failure of luminal mammary epithelial cells to differentiate (Siegal and Muller, 2010).  
These aforementioned transcription factors are an example of some of the downstream 
targets of hormones and growth factors that regulate mammary development. By altering 
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the expression of these transcription factors regulation of mammary development is able 
to occur. 
T-Box Genes and the Mammary Gland 
Transcription factors are not just present during lactation and pregnancy. The 
establishment of the rudimentary mammary gland during embryonic mammary 
development also relies on transcription factors. Two of these transcription factors are T-
box (Tbx) 2 and Tbx3. These transcription factors are examples of Tbx genes, which are 
a family of transcription factors that were first discovered in 1927. Today, 18 Tbx genes 
have been identified and can be categorized into five subfamilies (T, Tbx 1, 2, 6 and 
Tbr1; Naiche et al., 2005). These genes are expressed in several different tissue types and 
are critical during embryonic development when these transcription factors aid in the 
establishment of germ layers and organs (Abrahmas et al., 2010).  
All Tbx transcription factors contain a “T-box” DNA binding domain also known 
as the Tbx binding element. The Tbx binding element is 180 amino acids in size and is 
highly conserved between all members of the family (Naiche et al., 2005; Coll et al., 
2002). Both Tbx2 and Tbx3 contain this highly conserved domain however there are 
differences within their structure. In contrast to other Tbx family members Tbx2 and 
Tbx3 regulate development by binding DNA and repressing transcription (Rowley et al., 
2004).  In order to do so, Tbx2 and Tbx3 contain specific structural domains, called 
repressor domains. Tbx2 contains two repressor domains located near the N-terminal 
domain (amino acids 1-53) and carboxy terminal domain (amino acids 529 -573) of the 
protein (Abrahams et al., 2010). In contrast to Tbx2, Tbx3 contains only one repression 
domain between amino acids 567 to 623 located near the carboxy terminal domain 
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(Weiwei Fan et al., 2004). Despite variation in protein structure, the DNA sequence 
encoding for the Tbx2 and Tbx3 transcription factors are 95% homologous to one another 
(Coll et al., 2002). Consequently, these transcription factors are considered to be very 
similar to one another in both form and function. 
Tbx2 and Tbx3 are responsible for regulating the expression of many different 
genes during embryonic and postnatal development. One of the genes that these 
transcription factors regulate is the p19-Alternate Reading Frame (P19ARF), promoter 
also known as p14-ARF in humans (Carlson et al., 2002; Platonova et al., 2007; Rowley 
et al., 2004). This alternate reading frame is involved in the P19ARF-Mdm2-P53 
pathway which is responsible for controlling cell cycle (Carlson et al., 2002; Platonova et 
al., 2007; Rowley et al., 2004). When Tbx2 and Tbx3 represses transcription of the 
p19ARF, there is an increase in cellular proliferation, inhibition of cellular senescence, 
and a decrease in cellular apoptosis (Platonova et al., 2007).  
By inhibiting cellular senescence, which is a state in which cellular growth is 
arrested (Collado et al., 2007); Tbx2 and Tbx3 alter cellular growth. This is believed to 
be one of the mechanisms through which Tbx2 and Tbx3 are involved in tumerogenisis 
within the mammary gland (Rowley et al., 2004). The implications of what is known 
about Tbx2 and Tbx3 in inhibiting senescence and how it translates to our research will 
be discussed later in the rationale and hypothesis section.  
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Role of Tbx3 and Tbx2 in the Mammary Gland 
Embryonic Mammary Development 
      Tbx3 has been found to play a key role in the formation of the mammary placodes 
from the mammary line. These placodes will eventually become the parenchyma of the 
mammary gland. In mice, Tbx3 is expressed at day 10.5 gestation, which is typically the 
time in which the mammary placodes are established. It is also thought that Tbx3 plays 
an active role in the formation of the mammary gland from the cells of the ectoderm 
(Hens and Wysolmeske, 2005). In humans, a haploinsufficency of Tbx3 is not lethal but 
results in Ulnar Mammary Syndrome (UMS). This disorder is characterized by mammary 
gland hypoplasia which further demonstrates the critical role of Tbx3 in mammary gland 
development (Carlson et al., 2002; Platonova et al., 2007).  
As stated previously, Tbx2 is a repressor much like Tbx3; however Tbx2 is not 
expressed within the epithelial buds of the mammary gland. Instead, Tbx2 is expressed in 
the mesenchyme of the developing embryonic mammary gland (Chapman et al., 1996). 
Tbx2 and Tbx3 function independently of each other and Tbx2 has been found to play a 
role in the regulation of adhesion molecules such as cadherins and integrans during 
embryonic development (Abrahams et al., 2010; Chen et al., 2001). As a result, it has 
been hypothesized that Tbx2 could play a role in the migration as well as invagination of 
the cells when the mammary placodes are being formed (Hens and Wysolmeske, 2005). 
Within our research we want to determine if Tbx2 is expressed within the stromal tissue 
of the mammary gland of adult cattle and if its function is similar to Tbx3 within this 
tissue type. 
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Role of GH and IGF-I on Tbx gene expression 
Within the mammary gland GH, IGF-I, and the transcription factors Tbx2 and 
Tbx3 are important regulators of mammary gland development and function. However, 
there is limited information on the interactions of these factors and their role in postnatal 
mammary gland development and function. Recent research has demonstrated that GH 
regulates Tbx3 gene expression in bone (Govoni et al., 2006). Within this study, GH 
deficient lit/lit mice were treated with exogenous GH and gene expression of Tbx3 was 
quantified (Govoni et al., 2006). In treated animals, Tbx3 expression significantly 
increased within bone tissue. Similar results were observed in a MC3T3-E1 osteoblast 
cell line when cells were treated with 100 ng/mL of GH. To determine if the increase in 
Tbx3 gene expression was mediated directly by GH, cells were pre-treated with 
 IGFBP-4, a known inhibitor of IGF-I, and a similar increase in Tbx3 was observed. 
These findings suggest that the increase in Tbx3 gene expression is mediated directly by 
GH, independent of IGF-I (Govoni et al., 2006). Knowing that GH and IGF-I are needed 
during mammary development and that GH alters Tbx3 expression in bone, one of the 
objective of our research was to evaluate the effect of these growth factors on Tbx3 gene 
expression within the mammary gland. 
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RATIONALE AND HYPOTHESES 
It is well established that hormones, growth factors, and transcription factors 
regulate mammary gland development. Two of these transcription factors are Tbx2 and 
Tbx3. Tbx2 and Tbx3 are expressed in the early stages of embryonic development and 
are responsible for establishing the early structures of the mammary gland.  Little is 
known about the postnatal role, gene expression and regulation of Tbx2 and Tbx3 in the 
mammary gland. The majority of what is known about these genes in postnatal mammary 
development is often pertaining to cancer rather than their function in healthy mammary 
tissue (Rowley et al., 2004). In regards to the bovine mammary gland, to our knowledge, 
the role of these genes in bovine mammary development is not known and has yet to be 
evaluated.   
It is also well known that mammary development is regulated by two growth 
factors, GH and IGF-I as previously discussed in the literature review. Recent research 
also suggests that the somatotropic axis may regulate Tbx3 expression in other tissues. 
Knowing that Tbx2 and Tbx3 are essential for mammary development and that GH and 
IGF-I are involved in mammary development we developed the following hypotheses: 
1) GH and IGF-I will increase Tbx3 expression in MEC. 
2) GH and IGF-I will increase Tbx2 expression in MEC. 
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MATERIALS AND METHODS 
 
Mammary Tissue 
Mammary tissue for RNA extraction was obtained from mammary parenchymal tissue 
from lactating cattle at slaughter. Tissues were excised and snap frozen in liquid nitrogen 
and stored at -80 ºC.  
 
Cell Culture 
MAC-T cells used in experiments were generously provided by W. Cohick  
(Rutgers University) and M. Akers (Virginia Polytechnic Institute and State University). 
Primary MEC were established using a protocol from Wellnitz and Kerr, 2004. 
Mammary cells were obtained from lactating dairy cows at slaughter. Immediately 
following slaughter, the mammary gland was removed from the animal and tissue was 
aseptically removed from the mammary gland and transported back to lab on ice in 
Hank’s Balanced Salt Solution (HBSS; Invitrogen, Carlsbad,CA), 5 µg/mL Fungizone 
(Sigma-Aldrich, St. Louis, MO), 20 µg/mL Penicillin (Thermo Fischer Scientific, 
Waltham, MA), 20 µg/mL Streptomycin (Thermo Fischer Scientific, Waltham, MA) , 
and 25 µg/mL Gentamycin (Sigma-Aldrich, St. Louis, MO). When culturing primary 
MEC, culture contamination with fibroblasts was common. To remove this cell type 
selective trypsinization was performed and the fibroblasts were cultured separately.  
When subculturing cells, MEC were grown to 80% confluence in DMEM 
(Invitrogen, Carlsbad,CA)  supplemented with 10% FBS (Thermo Fischer Scientific, 
Waltham, MA), 10 µg/ml Penicillin/Streptomycin, 0.1 µg/mL Fungizone, 25 µg/mL 
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Gentamycin and 5 µg/mL Bovine Insulin (Sigma-Aldrich, St. Louis, MO). Cells were 
incubated at 37º C/ 5% CO2. MACT cells and fibroblasts were cultured in the same 
conditions as MEC. 
For experiments, MAC-T and MEC were plated at a density of 100,000 cells/well 
in Phenol Red Free (PRF) DMEM (Sigma-Aldrich, St. Louis, MO) supplemented with 
10% FBS. When plating fibroblasts, 150,000 cells/well were plated. At 70% to 80% 
confluence, all cells were serum deprived for 24 hours in PRF/Serum-Free DMEM 
supplemented with 0.2% BSA (Sigma Aldrich, St. Louis, MO) and 30nM sodium selenite 
(Sigma-Aldrich, St. Louis, MO). After serum depravation, cells were rinsed with PBS 
and treated with either control media containing 0.02% BSA and 30 nM sodium selenite 
(Sigma-Aldrich, St. Louis, MO) or control media plus 100 ng/mL of bovine GH, 500 
ng/mL bovine GH, 100 ng/mL human IGF-I or  200 ng/mL human IGF-I (National 
Hormone and Peptide Program, Torrance, CA) for 24h or 48h 
 
RNA extraction 
For cell cultures, media was removed from cells and cells were rinsed with PBS 
prior to addition of 1mL TriReagent (Sigma-Aldrich, St. Louis, MO). For mammary 
tissue, tissue was ground in a mortar cooled with liquid nitrogen prior to the addition of 
TriReagent. RNA was extracted using a Qiagen Mini Kit according to the manufacturer`s 
protocol (Qiagen, Valencia, CA). Genomic DNA was removed from samples through the 
use of a DNA Free Kit (Ambion, Foster City, CA). Samples were diluted to a 
concentration of 30 ng/µL using a Nanodrop spectrophotometer. Quality of RNA was 
determined by using Experion analysis (BioRad, Hercules,CA).  
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Reverse Transcription (RT) - PCR 
RT-PCR was performed using 300 ng total RNA with OligoDT primer (Ambion) and 
master mix containing 5.5 µL of 5x Buffer  (Invitrogen, Carlsbad, CA), 1 µL dNTP 
(Promega, Madison, WI), 2 µL DTT and 0.5 µL Superscript II (Invitrogen, Carlsbad, 
CA) for a total reaction volume of 20 µL. The samples and master mix underwent a 
standard reverse transcription protocol starting at 70 ºC for 10 min, 4ºC for 20 min, 37ºC 
for 3 min, 42ºC for one hour, 4ºC for 3 min, 90ºC for 2.5 min. Resulting cDNA was then 
diluted using 80 µL of Nuclease Free Water (Thermofisher Scientific, Waltham, MA) 
and stored at -20ºC. 
 
Real-time RT-PCR 
Primers were designed using Primer3 and NCBI BLAST. DNA oligos were synthesized 
by Integrated DNA Technologies (Coralville, IA; Table 1). The endogenous control 
gene selected was ribosomal protein subunit (RPS) 15 (Bionaz and Loor, 2007). 
Real-time RT-PCR was performed using Power SybrGreen Master Mix (Invitrogen, 
Carlsbad, CA) and the ABI 7900 Fast Real-time PCR machine (Applied Biosystems, 
Foster City, CA). The total volume of the reaction mixture was 25 µL containing 5 µL of 
cDNA, 3 uL of nuclease free water, 1 µl each  of 10 nM forward and reverse primer and 
10µL of Sybergreen. For the Tbx3 master mix only 0.5µL of each forward and reverse 
primer was used along with 4 µL of nuclease free water. PCR cycling conditions used 
were a standard cycle with a starting stage of 50 ºC for 2 min and 95 ºC for 10 min. The 
PCR entered the second stage at 95 ºC for 15 sec and 60 ºC  for 1 min for 40 cycles. The 
third and final stage consisted of 95 ºC for 15 sec and 60ºC for 15 sec with a 2% ramp to 
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95 ºC for 5 min. ∆Ct values were obtained and  these values were used to calculate the 
∆∆Ct values to determine changes in gene expression (Livak and Schittgen, 2001). 
Changes in gene expression are expressed as fold changes from the control treatments. 
 
PCR 
PCR was used as a method to optimize primers and visualize gene expression. Primers 
used were the same as those that were described in the real time RT-PCR portion of the 
methods section. The total volume of the reaction mixture was 25 µL containing 5 µL of 
cDNA, 5.5µL of nuclease free water, 12.5 µL of Go Taq Green Master Mix (Promega, 
Madison, WI) and 1.0 µL of forward and reverse primers. PCR cycling conditions with a 
starting stage at 95ºC for 3 min. The thermocycling parameters for the second stage were 
94ºC for 30 sec, 60ºC for 1 min, 72ºC for 1 min repeating for 40 cycles concluding at 
72ºC for 5 min. PCR products were then run in a 2% agarose gel and visualized using UV 
light.  
 
Statistical Analysis 
Data were analyzed by ANOVA using SAS program (Version 2.9, SAS Institute Inc, 
Cary, NC, USA). Data were evaluated by comparing control treated cells verses hormone 
treated cells. The differences between the least square means of control vs. hormone 
treated cells were used to determine P values. Statistical significance was considered at P 
≤ 0.05 
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RESULTS 
 
IGF-I stimulates Tbx3 expression in bovine MEC 
At both 24h and 48h time points we did not observe an effect of GH treatment on 
Tbx3 gene expression (Figure 1; P ≥ 0.74). However, IGF-I at both doses increased Tbx3 
expression significantly from controls (Figure 2; P ≤ 0.03) at 24h but not at 48h (Figure 
2; P ≥ 0.17). To determine if IGF-I treatments were effective at both time points, IGFBP3 
mRNA expression, which is known to increase in response to IGF-I, was determined in 
treated and control cells. A significant increase in IGFBP3 mRNA was observed at both 
time points for both doses (Figure 3; P ≤ 0.001), demonstrating that IGF-I treatment was 
effective.  
 
Tbx3, but not Tbx2, is expressed similarly in the mammary gland, fibroblasts and MEC. 
To evaluate our second hypothesis we determined Tbx2 gene expression in MAC-
T cells that were treated with either GH or IGF-I. We were unable to detect expression of 
Tbx2 in the MAC-T cell line. To determine if this lack of expression was specific to the 
MAC-T cell line, we isolated primary MEC and evaluated Tbx2 expression. Similarly, 
Tbx2 expression was not detectable (Figure 4 and Figure 5).  Based on our preliminary 
findings that Tbx2 is expressed in mammary gland tissue (Figure 4 and Figure 5) and 
previous findings that Tbx2 is highly expressed in lung fibroblasts (Teng et al., 2007), we 
hypothesized that Tbx2 expression may be in mammary fibroblasts. Fibroblasts were then 
isolated from the stroma of the mammary gland to detect Tbx2 expression. We observed 
that Tbx2 is highly expressed in fibroblasts when compared to the mammary gland 
(Figure 4 and 6 ; P = 0.01). To determine if Tbx3 was also differentially expressed we 
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evaluated Tbx3 gene expression within the mammary gland and all cell types. We 
determined that all cell types and mammary tissue expressed Tbx3 mRNA and gene 
expression did not vary significantly from the expression in the mammary gland (Figure 
6; P ≥ 0.14).  
 
 
GH and IGF-I treatment did not alter Tbx2 and Tbx3 gene expression in fibroblasts 
Based on our findings that Tbx2 expression in the bovine mammary gland was 
primarily in fibroblasts, these cells were used as the model to determine the effect of GH 
and IGF-I on Tbx2 gene expression. In addition, we wanted to determine if treatment 
with GH or IGF-I would have an effect on Tbx3 expression in these cells. We did not 
observe an effect of GH or IGF-I treatment on either Tbx2 or Tbx3 gene expression 
(Figure 7; P ≥ 0.76). To determine if the cells were responsive to treatment, IGFBP3 gene 
expression was evaluated. As expected, when cells were treated with IGF-I, IGFBP3 
expression increased 63-fold from control fibroblasts cells (Figure 7; P value < 0.0001).  
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FIGURE LEGENDS 
Figure 1: GH treatment did not alter Tbx3 gene expression. All MAC-T cells were 
cultured in control media (0.02% BSA) and treated with 100 ng/mL GH (GH100), 500 
ng/mL GH (GH500) or without GH (control) for 24h or 48h.  Data are presented as fold 
change from the control and expressed as mean ± SE. No significant differences were 
observed at P ≥ 0.74. GH = growth hormone, IGF-I = insulin-like growth factor-I,  h= 
hours, SE= standard error, BSA = bovine serum albumin. 
 
Figure 2: IGF-I treatment increased Tbx3 expression. All MAC-T cells were cultured in 
control media (0.02% BSA) and treated with 100 ng/mL IGF-I (IGF100), 200 ng/mL 
IGF-I (IGF200) or without IGF-I (control) for 24h and 48h. Data are presented as fold 
change from the control and expressed as a mean ± SE. * indicates P ≤ 0.03. IGF-I = 
insulin-like growth factor-I, h= hours, SE= standard error, BSA = bovine serum albumin. 
 
Figure 3: Treatment with IGF-I significantly increased IGFBP-3 expression in MAC-T 
cells. IGFBP-3 expression was quantified for cells treated with 100 ng/mL IGF-I 
(IGF100), 200 ng/mL IGF-I (IGF200) or without IGF-I (control) for 24h and 48h. Data 
are presented as fold change from the control and expressed as a mean ± SE. * indicates 
 P ≤ 0.001. IGF-I = insulin-like growth factor-I, h= hours, SE= standard error, BSA = 
bovine serum albumin, IGFBP3 = insulin-like growth factor binding protein-3. 
 
Figure 4: Tbx2 expression is present in the mammary gland and fibroblasts. PCR 
products from mammary gland tissue (MG), MAC-T cells, MEC cells, and fibroblasts 
were run in an 2% agarose gel at 130 V. Bands were visualized using UV light. 
RSP15 = Ribosomal protein subunit 15, MG = mammary gland, MEC= mammary 
epithelial cells, UV = ultraviolet, PCR = polymerase chain reaction. 
 
Figure 5: Tbx2 mRNA is expressed in fibroblasts in the bovine mammary gland. Data 
are presented as fold change from the control and expressed as a mean ± SE. * indicates P 
≤ 0.02. ND = Not detectable, MEC = mammary epithelial cells, MG = mammary gland. 
 
Figure 6: Tbx3 is expressed similarly in all cell types in the bovine mammary gland. 
Data are presented as fold change from the MG and expressed as a mean ± SE.  A 
significant different was not observed at P ≥ 0.13. MEC = mammary epithelial cells,  
MG = mammary gland. 
 
Figure 7: GH and IGF-I treatment did not alter Tbx2 or Tbx3 expression in fibroblasts. 
Fibroblast cells were cultured in control media (0.02% BSA) and treated with 500 ng/ml 
GH (GH500), 200 ng/mL IGF-I (IGF200) or without growth factors (control) for 24h. 
Data are presented as fold change from the control and expressed as a mean ± SE.  
* indicates P ≤ 0.0001. GH = growth hormone, IGF-I = insulin-like growth factor-I, SE = 
standard error, IGFBP-3 = insulin-like growth factor binding protein-3. 
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TABLES 
Table 1:  Bovine Specific Primers 
Gene Primer Amplicon 
length (bp) 
Sequence (5’ to 3’) 
RPS15 Forward 151  GCA GCT TAT GAG CAA GGT CGT 
RPS15 Reverse 151  GCT CAT CAG CAG ATA GCG CTT 
Tbx3 Forward 101  ATC GCT GTG ACT GCA TAC CA 
Tbx3 Reverse 101  TCT CTC CTG CCA TTT CCA GT 
Tbx2 Forward 124 CTT GCA GTG CTC CTC CTA 
Tbx2 Reverse 124 CAC GCA GCT TAA GAT CGA CA 
IGFBP-3 Forward 231 CAG AGC ACA GAC ACC CAG AA 
IGFBP-3 Reverse 231  TGC CCC CTA CTT ATC CAC ACA 
 
Primers were designed using Primer3 and NCBI Blast 
RPS15 = ribosomal protein subunit-15, Tbx2 = T-box 2, Tbx3 =T-box 3,  
IGFBP-3 = Insulin-like binding protein-3
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Figure 1: 
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Figure 6: 
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Figure 7: 
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DISCUSSION 
Tbx2 and Tbx3 expression in the bovine mammary gland 
There is a limited amount of information about Tbx2 and Tbx3 gene expression in 
adult mammary tissue. Consequently, the regulatory mechanisms, expression patterns, 
and roles of these genes in postnatal mammary development are not known. Within our 
research, we observed that there is differential expression patterns and regulation of Tbx2 
and Tbx3 within the bovine mammary gland. We determined that Tbx2 expression is 
localized within mammary fibroblasts whereas we were unable to detected expression in 
MEC. Our observations of Tbx2 expression in fibroblasts are in agreement with data 
from a study conducted by Teng et al in 2007. Within this study researchers observed 
endogenous Tbx2 expression in the WI-38 fetal lung fibroblast cell line (Teng et al., 
2007). Other studies have evaluated Tbx2 expression in fibroblasts. However these 
fibroblasts did not express Tbx2 endogenously and were transfected with a plasmid 
containing a Tbx2 gene construct (Teng et al., 2007; Chen et al., 2001). In adult human 
tissues it is known that heart, kidney, lung, mammary and ovarian tissue express Tbx2 
(Law et al., 1995). However differential gene expression of Tbx2 and Tbx3 has yet to be 
evaluated within these tissue types. Further research is needed to evaluate the expression 
patterns within these tissues.         
 The expression pattern of Tbx2 in the fibroblasts in adult mammary tissue is 
similar to what is observed in the embryonic mammary gland. Tbx2, but not Tbx3, is 
expressed within the mammary mesenchyme which will later become the stroma  
(Chapman et al., 1996). This conserved expression pattern suggests that it may be 
necessary for postnatal mammary gland development and therefore must be maintained. 
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In embryonic development, Tbx3 but not Tbx2 is expressed within the mammary 
placodes which will later become the parenchyma (Chapman et al., 1996). Interestingly, 
within our experiments we did observe that all cell types evaluated express Tbx3 similar 
to one another. This suggests that Tbx3 expression within the fibroblasts may be 
necessary postnatally however expression is prevented during the embryonic stages. 
Overall, a potential reason for this differential gene expression between mammary 
fibroblasts and MEC could be the need for tissue predominance to change throughout 
mammary gland development. 
 As the mammary gland matures and transitions through puberty, pregnancy and 
lactation, the predominate tissue type will change. There are several examples of 
regulatory factors within the bovine mammary gland that will increase or decrease based 
on the stage of mammary gland development and effect mammary tissue predominance. 
An example of one of these factors is the transforming growth factor-β1 (TGFβ1: Akers, 
2002; Plaut et al., 2003; Plath et al., 1997). This growth factor has been found to alter the 
predominance of the mammary stroma and parenchyma especially as the gland prepares 
for lactation to cease during involution. Transforming growth factor-β1 does this by 
facilitating an increase in stromal cell proliferation, ECM break down, and MEC 
apoptosis (Akers, 2002; Plaut et al, 2003; Plath et al., 1997). Transforming growth factor-
β1 concentrations within the mammary gland will remain low throughout pregnancy and 
lactation. However, as the gland prepares for involution TGFβ1 concentration will 
increase significantly (Akers, 2002; Plath et al., 1997).       
 The temporal variation in TGFβ1 concentration is in direct correlation with the 
stages at which a greater number of MEC are needed. This regulatory mechanism not 
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only demonstrates that tissue remodeling occurs frequently within the mammary gland 
but that Tbx2 and Tbx3 could be facilitating a similar role with the gland. Studies have 
evaluated the effects of over expressing Tbx2 in the embryonic fibroblast cell line, 
NIH3T3 (Chen et al., 2001). The results from this study suggest that Tbx2 reduces 
collagen gene expression as well as cell adhesion molecules such as cadherins (Chen et 
al., 2001). Within the mammary gland, collagen comprises the ECM of the stroma and is 
produced by the fibroblasts. Without the ECM, MEC cannot differentiate properly and 
therefore are not able to produce milk proteins. It is possible that Tbx2 may play a role in 
regulating collagen production of mammary fibroblasts and therefore may affect MEC as 
the gland transitions from one state to another. It is known that Tbx3 increases cellular 
proliferation however it has also been determined that Tbx3 gene expression prevents 
differentiation. Therefore further research needs to be conducted in MEC and fibroblasts 
to determine how Tbx2 and Tbx3 expression changes during differentiation.  
 Within our research, we also observed differential regulation of the Tbx genes 
within the mammary gland. In MAC-T cells, IGF-I increased Tbx3 gene expression. 
However, in mammary fibroblasts, both Tbx2 and Tbx3 expression remained unaltered in 
the presence of GH and IGF-I treatment. This suggests that IGF-I affects Tbx3 in MEC 
and potentially does not affect Tbx2 or Tbx3 expression in fibroblasts of the stroma. 
Therefore, this could be a mechanism through which proliferation of the MEC increases 
differently from the stroma of the gland.  It is believed that Tbx2 and Tbx3 are expressed 
and function similar to one another (Coll et al., 2002). However, our findings suggest that 
there is differential expression as well as differential regulation of expression of Tbx2 
and Tbx3 in the bovine mammary gland. Further studies are need to evaluate Tbx2 and 
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Tbx3 expression during the different stages of development in order to determine how 
Tbx2 and Tbx3 expression changes within the parenchyma as well as the stroma over 
time  
 
Regulation of Tbx2 and Tbx3 by the Somatotropic Axis 
In order for Tbx2 and Tbx3 to facilitate cellular proliferation and inhibit 
senescence, the genes for these transcription factors must be transcribed. However, in an 
effort to prevent uncontrolled cellular proliferation to allow for cellular senescence, the 
expression of these genes is tightly regulated. Within embryonic development it has been 
determined that Tbx2 and Tbx3 expression is regulated by a several signaling molecules 
in many different tissue types (i.e., BMP, Shh: Trumpel et al., 2002).  However, the 
mechanisms for regulating Tbx2 and Tbx3 expression in the adult bovine mammary 
gland have yet to be determined. Within our research, we observed that IGF-I increased 
Tbx3 gene expression within MAC-T cells. This suggests Tbx3 may be a key mediator of 
IGF-I action within the mammary gland. Further research is needed to determine if IGF-I 
is directly mediating the increase of Tbx3 expression within the gland or if there are other 
regulatory mechanisms involved in this process. 
 Our observations are in contrast to what was found in a study by Govoni et al., in 
2006 where GH treatment increased Tbx3 gene expression independent of IGF-I (Govoni 
et al., 2006). Within our cells, GH did not have an effect on Tbx3 gene expression. The 
difference in findings between our work and the previous study could be due, in part, to 
variation in the receptors present on these two tissue types and as a result the response of 
the tissues to GH and IGF-I. It is well established that GHR are present on the germinal 
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portion of bone (Le Roith et al., 2001; Hadley and Levine, 2007). However the presence 
of a functional GHR in the MEC is debatable (see Hormones section of literature review). 
Therefore, it is not clear if GH does not alter Tbx3 expression in MEC or if GH cannot 
have an effect on these cells due to a lack of a functional GHR.  
When fibroblast cells were treated with either GH or IGF-I we did not observed a 
change in Tbx2 and Tbx3. It is known that GHR are present on fibroblasts and that these 
cells also produce paracrine IGF-I which in turn can act on MEC. However, our results 
suggest that within the mammary fibroblast cells of lactating animals there is no effect of 
the somatotropic axis on Tbx3 and Tbx2 expression. Further studies are needed to 
determine if this remains the same throughout the different stages of mammary 
development. While IGF-I effects Tbx3 gene expression in MEC there may be other 
growth factors or hormones that are needed in order to facilitate an increase in Tbx2 or 
Tbx3 gene expression within mammary fibroblasts 
 
Role of Tbx3 in mediating the Somatotropic Axis 
 Within the mammary gland one of the mechanisms through which mammary 
growth occurs is through cellular proliferation induced by IGF-I (Akers., 2002; Cohick., 
1998).  IGF-I increases cellular proliferation by activating several cell signaling cascades 
that result in alterations of the cell cycle. Some of these pathways that are activated are 
the ras/raf/mapk pathway and β-catenin which in turn will activate cyclin D1 and c-myc 
(Akers, 2002; Hadsell et al., 2002). In a study conducted by Carlson et al., mammary 
fibroblast cells were transfected with plasmids that would cause over expression of Tbx3, 
H-Ras, and Myc (Carlson et al., 2002). When Tbx3 was over expressed in combination 
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with H-Ras and/or Myc there was an increase in the immortalization of the cells (Carlson 
et al., 2002). These results suggests that Tbx3 was working in cooperation with Myc and 
H-Ras by down regulating the p19ARF resulting in cellular immortalization of MEF 
(Carlson et al., 2002). As stated previously, IGF-I activates several cell signaling 
cascades of which myc and ras belong to. Therefore, it is possible that by repressing 
P19ARF that Tbx3 facilitates the actions of IGF-I resulting in an increase in cellular 
proliferation of MEC. Further research is needed within this area to identify the 
downstream targets of Tbx3 when MEC are treated with IGF-I. 
 In summary, we know that Tbx2 and Tbx3 are needed during embryonic 
mammary development. Within our data, we observed that these transcription factors are 
expressed in the adult mammary gland and the differential expression pattern observed 
during embryogenesis is maintained into adulthood. We also observed in MEC that IGF-I 
increases Tbx3 gene expression within these cells. However we did not observed an 
effect of GH treatment on Tbx3 expression in MEC. This suggests that Tbx3 may 
mediate the actions of IGF-I on the mammary gland and that the effects of GH treatment 
on Tbx3 gene expression may be tissue type specific. Alternately, we did not observe an 
effect of GH or IGF-I treatment on Tbx2 or Tbx3 expression in mammary fibroblasts. 
Further research is needed to evaluate growth factors and hormones that may be involved 
in modulating this genes expression in this cell type. In future research, Tbx2 and Tbx3 
expression needs to be evaluated at the different stages of mammary development 
especially during differentiation. We observed that Tbx3 may be mediating the actions of 
IGF-I on MEC, but further research is needed to identify the downstream targets of Tbx3 
within the bovine mammary gland. 
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APPENDICES 
 
Appendix 1: Protocol for excising tissue from the bovine mammary gland 
 
1. Set up the area that you will be using as a work surface. This entails washing 
down the counters with a 1:10 bleach solution following up by wiping the surface 
down with 70% Ethanol. Place white lab bench top covering over the work 
surface. 
 
2. Set up you tools that will be utilized to excise the tissue. Keep autoclaved scissors 
and tweezers in tin foil until they are ready to be used. Affix scalpel blade to the 
scalpel holder. Leave the blade covered by the protective foil wrapper so the 
sterility is maintained. 
 
3. Once the udder has been presented to you, prepare the udder for tissue excision. 
Observe the udder for any signs of abnormalities (i.e.: slack quarter ect). Avoid 
any regions that appear to be damaged due to mastitis. If there are any gross 
abnormalities with the gland obtain samples from another gland. 
 
4. Wash a portion of the gland with 70% Ethanol, taking care to clean the udder to 
remove any debris.  Make and incisions with the scalpel. Remove adipose tissue 
and connective tissue using forceps 
 
5.  Utilize alcohol to clean instruments, changing for new sterile ones if necessary. 
Take care not to damage the tissue with the Ethanol. Excise the parenchymal 
tissue as carefully and cleanly as possible.  Large vessels, mammary fat pad, and 
other undesired tissue should be avoided however this can always be removed 
prior to mincing once back at the lab 
 
6. Once the tissue has been excised, carefully place the tissue in a falcon tube 
containing 35 mL of HBSS containing Penn/Step, Fungizone, Glucose and 
Gentamycin that has been kept on ice. Do not leave at room temperature as this 
can decrease the efficacy of the antibiotics. 
 
7. Transport the tissue in media on ice back to the lab where it will be prepped for 
isolation 
 
• Take tissue samples from the different quarters of the mammary gland ensuring 
that you clean each surface well before making an incision. By doing this you are 
not only getting tissue from different portions of the mammary gland but checking 
the udder for any signs of mastitis or other abnormalities that could impact the 
success of the isolation. 
 
• If collecting from more than one animal ensure that all tubes are labeled properly 
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Appendix 2: Protocol for the isolation of bovine mammary epithelial cells 
 
1. Clean the outside of the falcon tubes clean them with 70% Ethanol so as not to 
introduce any contaminates to the hood.  
 
2. Take fresh flacon tubes and add  35 mL HBSS .  Aspirate off the HBSS that you 
transported the tissue in and remove the tissue from the transport tube and place it 
in the new tube. Swirl tissue around and then remove this HBSS. This is done to 
rinse the tissue prior to mincing in an attempt to remove any foreign matter and 
detritus 
 
3. Mince tissue in flacon tube using a pair of scissors. Change scissors in between 
tubes so as to prevent contamination. Rinse tissue frequently with HBSS to 
remove milk as well as blood. Use transfer pipettes as it is easier than using the 
vacuum.  Mince until the tissue is approximately 1-5 mm3 in size. 
 
4. Once tissue has been minced and cleaned it will be added to the digesting 
mixture.  The digesting mixture should contain the following: 250 mL of HBSS,  
.5 mg/mL collagenase IV, .4 mg/mL Dnase I, .5 mg/ml hyaluronidase, 50 ug/mL 
Gentamycin, and 2.5 ug/mL fungi zone.  The digesting mixture should be 
STERILE FILTERED prior to use.  In the hood add the digesting mixture to an 
AUTOCLAVED Erlenmeyer flask with a spinner bar. Allow the tissue to remain 
in this mixture for three hours 
 
5. Upon completing of the incubation utilize a large metal strainer to remove large 
pieces of undigested tissue as well as fat. Place the resulting liquid into falcon 
tubes and centrifuge at 40 G (rcf) for 5 min.  
 
6. Resuspend in fresh HBSS and filter again through a smaller metal filter. Place the 
resulting liquid into falcon tubes and centrifuge at 40 G (rcf) for 5 min. Remove 
HBSS and resuspend in fresh HBSS and filter through a cell strainer (100 um).  
Centrifuge at 40 G (rcf) for 5 min.  
 
7. Resuspend the cell pellet in culture media. If there appears to be still some debris 
use the cell strainer again but do not re-centrifuge. Plate out the cells and allow 
them to incubate for 30 min at 37 degrees Celsius/5% CO 
 
8. After 30 minutes gently decant off the media. The cells left behind should be 
fibroblasts 
 
 
9. Watch cells very carefully for ANY signs of contamination. Also watch for 
fibroblast growth and use the “Removing Fibroblast Protocol” to prevent 
overgrowth of the culture with fibroblasts.  
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Appendix 3: Standard and PRF Dulbecco’s Modified Eagle Medium Preparation 
 
To Prepare 1X Liquid Medium 
1. Measure out 5% less distilled water than desired total volume of medium, 
using a   mixing container that is as close to the final volume as possible 
 
2. Add powdered medium to 15 to 30°C (room temperature) water with 
gentle stirring (DO NOT heat water) 
 
3. Rinse out inside of package to remove all traces of powder 
 
4. Add 3.7 g of Sodium Bicarbonate per liter of medium 
 
5. Dilute to a desired volume with water. Stir until dissolved taking care not 
to over-mix 
 
6. Adjust pH of medium to 0.2-0.3 below desired final working pH. Use of 
1N Sodium Hydroxide or 1N Hydrochloric Acid is recommended. After pH 
has been adjusted, keep container closed until media is filtered 
 
7. Sterilize immediately by membrane filtration 
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Appendix 4: MAC-T/MEC/Fibroblast cell subculture 
 
1. Bottles of media, PBS, and 50% Trypsin-EDTA/50% PBS should be warmed 
prior to usage. Care should be taken so that the media does not stay in the water 
bath for prolonged periods of time. Trypsin should never be placed directly in the 
water bath. 
 
2. Clean work area prior to usage with 70% Ethanol. Clean bottles from the water 
bath with 70% Ethanol prior to inserting them into the hood.  
 
3. Remove media from the plates using vacuum aspiration. Take care so as not to 
damage or disturbed the cells 
 
4. Add 2-3mL of warmed PBS to each plate. Do not add directly to the cells as this 
could dislodge them. Gently swirl PBS on the plate so as to remove any 
remaining media. Aspirate off PBS prior to addition of Trypsin-EDTA/PBS 
solution. 
 
5. Add 2-3 mL of Trypsin-EDTA/PBS to each plate. Place plates in incubator. 
a. For MAC-T: Allow cells to incubate in the presence of Trypsin-
EDTA/PBS for 7-10 min 
b. For MEC: Allow cells to incubate in the presence of Trypsin-EDTA/PBS 
for 25 min 
c. Fibroblasts: Allow cells to incubate in the presence of Trypsin-EDTA/PBS 
for 6 min 
 
6. Check plates at the end of trypsinzation to ensure that all cells have lifted then add 
media to stop the action of the enzyme. Using a cell scraper is sometimes needed 
for these cells. Be gentle when using the cell scraper so as to prevent cellular 
damage and cell clumping. 
 
7. Add contents of the plate to a 50 mL falcon tube and centrifuge to form a cell 
pellet 
a. For MAC-T and MEC: 600 rpm for 6.5 min 
b. For Fibroblasts: 1400rpm for 4.5 min 
 
8. After centrifugation, aspirate off media and resuspend cells in fresh media. The 
amount of media added to the pellet will depend on the purpose for these cells. If 
subculturing pass add 10 mL of media for every plate passed.  
 
9. Plate cells and return them to the incubator. Cells will have to be subcultured 
again once they reach 70%-80% confluence 
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Appendix 5: Removal of Fibroblasts from Primary Bovine Mammary Epithelial 
Cell Culture 
 
HBSS Removal Technique 
1. Remove media from the primary BMEC and rinse gently with warm PBS several 
times. 
 
2. Add HBSS solution containing .5 ug/mL fungizone,100,000 U/mL Penn/Strep, 
and Gentamycin. 
 
3. Allow cells to incubate in the presence of HBSS for 3hrs at 37 degrees 
Celsius/5% CO2. 
 
4. Remove HBSS and wash again several times with PBS. Wash slightly vigorously 
so as to remove fibroblasts that may have changed morphology but not lifted.  
 
5. Add fresh media to the plate and return to the incubator 
 
Selective Trypsinization 
 
1. Add 2 mL of 25% Trypsin-EDTA/75% PBS 
 
2. Allow cells to incubate in the presence of trypsin for 3 min 
 
3. Remove cells from the incubator and examine the plate. Look to ensure that the 
fibroblasts have lifted and NOT the mammary cells 
 
4. Remove the trypsin and fibroblasts and rinse with PBS. Use some force when 
rising but do not be too vigorous as this will cause the mammary cells to detach. 
 
5. Add 2 mL of 25% Trypsin-EDTA/75% PBS to the plate  
 
6. Allow cells to incubate in the presence of trypsin for 10-12 min. Monitor the cells 
periodically throughout this incubation. Once the cells have changed morphology 
add media to deactivate the trypsin. 
 
7. Remove cells from plate and place media and cells in centrifuge. Spin cells at 600 
rpm for 6 min 
 
8. Resuspend  cells and plate out onto new plates containing on 5 mL of media per a 
plate. Allow the plates to incubate for half an hour. This is to remove any residual 
fibroblasts that may have remained after the first trypsinization. 
 
9. Decant off the media ensuring not to disturbed the fibroblasts that have adhered to 
the plate. Plate out decanted cells (performing a cells count at this point if need 
be) in culture media and allow to grow until confluence. 
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Appendix 6: RNA extraction 
 
1. Rinse experimental plates with PBS and remove. Then add 1 ml TRI Reagent 
(Sigma Aldrich, at no. T9424) to each well and scrape well with pipette tip so as 
to remove the cells. Transfer the contents of the well to a 1.5 mL eppendoff tube. 
 
2. Vortex the TRI Reagent mixture to homogenize. Allow the tubes to incubate for 5 
min if extracting RNA immediately. If not, tubes should be stored in the freezer at 
-80 °C. 
 
3. Add 200 uL chloroform to each tube. Mix by inverting 5 -7 times and allow for it 
to incubate at room temperature for 2-3 min. *Centrifuge these tubes at 12000 x g 
for 15 min 
 
 
4. Transfer the aqueous phase into a new eppendorf tube taking care not to disturb 
the other layers. The total volume transferred will be close to 500 µL. Next Add 
one volume (500 uL) of 70% EtOH to each tube and vortex 
 
5. Transfer 700 uL of the sample into the RNA east Spin Column and centrifuge 
8,000 X , 30s. Discard the resulting flow through and add 700 µL RWI wash 
buffer. Take care to avoid adding any liquid directly onto the filter as this could 
cause a decrease in RNA yield. Centrifuge spin column again at 8,000 X g 30s 
 
6. Discard the flow through and collection tube put the filer on the new collection 
tube. Add 500 uL of Buffer RPE to spin column ensuring that 100% Ethanol has 
been added to the buffer prior to use. Centrifuge 8,000 x g, 30s and discard the 
flow through. 
 
7. Add 500 uL of Buffer RPE and centrifuge at 8,000 X g for 2 min. Discard the 
flow through and centrifuge at 8,000 X g 1 min. Discard the flow through and 
collection tube, put the filter on the new collection capped tube 
 
8. Add  50uL of Rnase free water to the spin column and centrifuge at 8,000 X g for 
1 min. Take 35-40 uL from the collection tube and put back on the filter 
centrifuge at 8000 X g, 1 min 
 
9. Collect the eluted RNA, in the capped collection tube, keep on ice, and spec it in 
the Nanodrop. Aliquot it and store in the -80 freezer 
 
• When extracting RNA from fibroblasts centrifuge for 15 min at 4°C 
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Appendix 7: Turbo DNA-Free Protocol 
 
1. Thaw the reagents (10x Turbo DNase Buffer, Turbo DNase, DNase inactivation 
reagent) on ice. 
 
2. Add 0.1 volume of 10x turbo Dnase Buffer (i.e.: 5 uL of 50 uL RNA sample) and 
1 uL Turbo Dnase to the RNA sample and mix gently. This is for routine DNase 
treatment with RNA concentration of 10ug/50uL of sample. If it is more than this 
con. Dilute your sample to have 10 ug/50 uL using C1V1=C2V2 
 
3. Incubate at 37 °C for 20-30 min 
 
 
4. Vortex the Dnase Inactivation reagent well as this mixture is very turbid. If 
performing DNA-Free treatment on a significant number of samples be sure to 
vortex frequently to prevent settling. Add 0.1 volume of resuspended DNase 
Inactivation reagent. 
 
5. Incubate for 5 min at room temp while mixing occasionally by flicking or tapping 
 
6. Centrifuge at 10000 x g for 1.5 min 
 
7. Transfer the supernatant to a fresh tube Note: Avoid disturbing the pellet 
 
8. The final DNA-free RNA con. Is determined by Nano drop 1000. 
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Appendix 8: Reverse Transcriptase PCR 
 
1. Thaw the reagents on ice( Ambion OligoDT, Invitrogen Superscript kit II 
containing DTT, 5X buffer and reverse transcriptase) 
 
2. Add 1uL of OligoDT to each 10uL of normalized RNA sample (300ng/10ul) in 8 
tube strips. This makes it a total of 11uL.NOTE:  Always include a positive and 
negative control 
     
3. Place these tubes into the thermocycler and state the desired RT PCR program 
(see below) and start step 1, 70˚C for 10min 
70˚C for 10min 
 4˚C for 20min 
 37˚C for 3min 
 42˚C for 1hr 
 4 ˚C for 3min 
 90˚C for 2.30 min 
 10˚C forever 
 
4. During the time of step 1, make the master mix. Do not add superscript until you 
are ready to add the master mix to the samples. 
 
Master Mix 
5X Buffer-  5.5uL 
dNTP-        1uL 
DTT-          2uL 
SuperscriptII   0.5 uL 
(Reverse transcriptase) 
 
NOTE: The above calculations are per sample, multiply it by the no. of 
samples+2 for pipetting errors. 
 
5. Pause the thermocycler when the temperature is dropping to 4˚C for the next step 
(step 2). Take the samples with RNA and Oligo DT out of the machine and keep 
it on ice. 
 
6. Add SSII to the master mix, mix gently. Add 9uL of master mix to each sample , 
making it a total of 20uL ensuring that samples are kept on ice while adding the 
master mix. Mix contents of tube with master mix by pippetting up and down 
several times. 
 
7. Place the samples back into the machine hit proceed and hit proceed again to 
move to step# 3. When RT is complete, add 80uL of Nuclease free water to 
samples and store in  -20˚C freezer. 
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Appendix 9: Designing Primers for PCR 
1. Go to www.pubmed.com. Ensure that you search “nucleotide” and then type in 
your gene of interest. Include the species 
 
2. Find your gene of interest and click on FASTA. This will present you with your 
gene of interest’s sequence.  Copy only CDS or CODING REGION of the 
sequence. If you do not use this your primers will not bind the correct sequence. 
 
3. Blast this sequence using the link entitled “ RUN BLAST” along the upper right 
of the webpage. This will compare your gene sequence to other sequences to 
ensure that you will be amplifying the right gene. 
 
4. Once the blast has been run, check the results to ensure that there are no matches 
for other genes in the species that you will be working with. 
 
5. Go to: http://frodo.wi.mit.edu/primer3/. Paste your sequence of interest in the 
large box. This program will construct your primers for you .Change the product 
size range. Usually you want your product to be between 80-300bp in size. Click 
“Pick Primers” 
 
 
6. Once you have the primers return to BLAST on the pubmed website and run a 
BLAST on these primers to ensure that they will amplify only the gene you want 
to look at in your species. 
 
7. Go to: http://genome.ucsc.edu/. Click on the tab entitled PCR located at the top of 
the webpage. Change the Genome tab to match the species you are working in. 
Enter your Forward and Reverse primer as determined by Primer3 (you can copy 
and paste it) 
 
8. Observe the temperatures at which these primers anneal. If they are close together 
for both the forward and reverse primer then you are all set 
 
 
9. Order your primers through Integrated DNA Technologies (IDT) at the following 
website: http://www.idtdna.com/Home/Home.aspx 
 
 
*Dilute and optimize your primers once you receive them by running both PCR 
and RT-PCR with an efficiency curve.  
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Appendix 10: Polymerase Chain Reaction 
 
1. Thaw reagents on ice (Promega Green Master mix, Tbx2 114 forward and reverse 
primer working aliquots, cDNA sample) 
 
2. Add 5uL of the cDNA to 8 tube strips once the master mix is added there will be a 
total volume of 25µL 
 
3. Make Master mix of 20uL for one reaction 
Nuclease free water     5.5µL 
Green master mix  12.5µL 
Forward Primer  1.0µL 
Reverse Primer   1.0µL 
 
NOTE: This is for one sample, multiply it by the number of samples plus two for 
pipetting errors. Be sure to include a negative and positive control. Transfer 20uL 
of the master mix to 8 tube strips 
 
 
4. Place the tubes into PCR machine and run the following program: 
 
94˚C for 3min 
 
94˚C for 30s 
 
60˚C for 1min 
 
72˚C for1min 
 
72˚C for 5min 
 
10˚C forever 
 
5. Once the PCR is complete ( about 21/2 hr), it is stored at 4˚C. 
 
 
 
 
 
 
 
X 40cycles 
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Appendix 11: Real time PCR 
 
 
1. Thaw the Reagents on ice.(Syber green wrapped in foil, forward and reverse 
primers, cDNA) 
 
2. Add 5uL of cDNA (diluted 1:5, 20uL of cDNA + 80uL of Nfree water) to the 
tubes. Make sure to pipette to the bottom of the tube. 
 
3. Make Master Mix. Amount will vary depending on the number of samples and 
number of genes. Turn off lights when using the syber green as it is light 
sensitive. Always add plus two for pippeting error and include negative and 
positive controls. 
 
             Master Mix 
2X Syber Green  10uL 
Forward Primer  1uL 
Reverse primer  1uL 
NFree water       3uL 
 
4. Add 15uL of master mix to each well in 96 PCR optical plate. Gently pipette 
contents of well with master mix to facilitate mixing. Avoid forming bubbles as 
this can result in incorrect values. 
 
5. Seal it with a PCR adhesive film tightly to prevent evaporation and centrifuge the 
plate at 1000RPM for 1-2minutes 
 
6. Run plate in the ABI 7900 HT Fast real time machine using the following 
protocol: 
 
Stage 1:  50 °C for 2 min 
   95°C for 10 min 
 
Stage 2:  95°C for 15 sec 
   60°C for 1 min 
*Repeat for 40 cycles 
 
Stage 3: 95°C for 15 s 
              60 °C for 15 s 
             95 °C with a 2% ramp for 2 min 
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